- Home
- FIG vs PEN Comparison
FIG vs PEN Comparison
Compare FIG & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | PEN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 12.6B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FIG | PEN |
|---|---|---|
| Price | $22.50 | $317.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 16 |
| Target Price | $30.80 | ★ $361.58 |
| AVG Volume (30 Days) | ★ 9.8M | 326.5K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.80 | ★ 1155.56 |
| EPS | N/A | ★ 1.70 |
| Revenue | $1,055,788,000.00 | ★ $1,403,665,000.00 |
| Revenue This Year | $39.15 | $13.48 |
| Revenue Next Year | $23.77 | $12.98 |
| P/E Ratio | ★ N/A | $186.32 |
| Revenue Growth | ★ 40.96 | 17.50 |
| 52 Week Low | $16.60 | $221.26 |
| 52 Week High | $70.40 | $362.41 |
Technical Indicators
Market Signals| Indicator | FIG | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 43.76 |
| Support Level | $21.62 | $315.42 |
| Resistance Level | $25.17 | $320.08 |
| Average True Range (ATR) | 0.96 | 1.62 |
| MACD | 0.15 | -0.06 |
| Stochastic Oscillator | 70.45 | 46.97 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma provides software solutions for design-related workflows. Since its founding in 2015, the company has introduced a variety of products and established an end-to-end platform for software design and product development. The firm's original and most important solution, Figma Design, was built as a collaborative tool to bring together designers and engineers in a real-time, multiple-simultaneous-editor workspace. Figma is headquartered in San Francisco, California, and completed its IPO in July 2025.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.